China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer
A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells|tumours which harbour deficiency in homologous recombination repair (HRR), The post China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer appeared first on Pharmaceutical Business review .
China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer
A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells|tumours which harbour deficiency in homologous recombination repair (HRR), The post China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer appeared first on Pharmaceutical Business review .